Arsenic Trioxide (Trisenox)

An inorganic compound with the chemical formula As2O3 that is used for the treatment of ACUTE PROMYELOCYTIC LEUKEMIA in patients who have relapsed from, or are resistant to, conventional drug therapy.

Also Known As:

Trisenox; Arsenic Oxide (As2O3); Arsenic Oxide (As4O6); Arsenic(III) Oxide; Arsenolite; Arsenous Anhydride; As2O3; As4O6; Diarsenic Trioxide; Naonobin; Tetra-Arsenic Hexaoxide; Tetra-Arsenic Oxide; Tetraarsenic Hexaoxide; Tetraarsenic Oxide; Trixenox; Tetra Arsenic Hexaoxide; Tetra Arsenic Oxide

Networked: 2610 relevant articles (414 outcomes, 528 trials/studies)

Relationship Network

Drug Context: Research Results

Inorganic Chemicals: 9
- Arsenicals: 309
  - Arsenic Trioxide: 2610
    - arsenoplatin-1: 1
- Oxygen Compounds: 12
  - Oxides: 2508
    - Arsenic Trioxide: 2610
      - arsenoplatin-1: 1

Experts

1.	Zhou, Jin: 43 articles (12/2021 - 11/2003)
2.	Ghavamzadeh, Ardeshir: 27 articles (01/2021 - 10/2005)
3.	Kwong, Yok-Lam: 27 articles (01/2021 - 07/2003)
4.	Tchounwou, Paul B: 24 articles (09/2021 - 09/2004)
5.	Alimoghaddam, Kamran: 24 articles (02/2018 - 10/2005)
6.	Lo-Coco, Francesco: 23 articles (10/2020 - 06/2006)
7.	Tallman, Martin S: 22 articles (01/2022 - 01/2002)
8.	Ghaffari, Seyed H: 22 articles (09/2020 - 09/2010)
9.	Jin, Jie: 20 articles (01/2021 - 06/2004)
10.	Bashash, Davood: 19 articles (01/2022 - 02/2012)

Related Diseases

1.	Acute Promyelocytic Leukemia 01/01/2011 - "Arsenic trioxide (ATO), a natural product that has improved the prognosis of acute promyelocytic leukemia (APL) from highly fatal to highly curable, has also been proven to be effective in treating BL cell lines through multiple pathways in our study. " 01/01/2020 - "Arsenic trioxide is the first-line treatment for acute promyelocytic leukemia (APL); however, abnormalities of ventricular repolarization and QT interval prolongation are the most common adverse effects. " 01/01/2017 - "Arsenic trioxide (ATO) is highly effective in the treatment of patients with acute promyelocytic leukemia (APL). " 05/01/2016 - "Arsenic trioxide (ATO) is highly effective for treating acute promyelocytic leukemia. " 11/20/2014 - "Arsenic trioxide (ATO) is a highly effective agent for the treatment of acute promyelocytic leukemia (APL). "
2.	Neoplasms (Cancer) 11/10/2015 - "Importantly, As2O3 treatment dramatically reduced GSC population in the intracranial GBM xenografts and increased the survival of mice bearing the tumors. " 02/01/2001 - "To examine the in vivo effect of As2O3, C3H mouse inoculated with syngenic SCC7 cells was treated by intratumoral injection of As2O3 (300 microg) every day, demonstrating that tumor mass was dramatically reduced on day 4, and revealed induction of apoptosis by TUNEL assay. " 12/01/2016 - "Arsenic trioxide (ATO) has been used successfully to treat acute promyelocytic leukaemia, and since this discovery, it has also been researched as a possible treatment for other haematological and solid cancers. " 10/07/2014 - "This study highlights a feasible drug delivery strategy to expand the use of arsenic trioxide for the effective treatment of solid tumors." 09/01/2020 - "On the other hand, arsenic trioxide (ATO) in combination with other agents effectively treated a number of blood malignancies, including PEL. "
3.	Leukemia 08/15/2012 - "However, the side effects and relatively low efficacy of As2O3 in treating other leukemias have limited its wider use in therapeutic applications. " 03/01/2005 - "In conclusion, As2O3 was effective in all 3 cell lines, suggesting that As2O3 may be a promising agent for the treatment of multidrug-resistant leukemia." 10/28/2016 - "In the present study, we evaluated the in vitro efficacy of arsenic trioxide (ATO) in RMS, a FDA-approved drug used in pediatric leukemia. " 03/31/2017 - "This study could lay the foundation of deciphering mechanisms of HL-60 cell apoptosis and give a new possible target to the clinical application for arsenic trioxide treatment for leukemia." 10/01/2016 - "In our study, runt‑related transcription factor 3 (RUNX3) was identified as a novel target gene affected by As2O3 and involved in mesenchymal stem cell (MSC)‑mediated protection of leukemia cells from As2O3‑induced apoptosis. "
4.	Multiple Myeloma 03/13/2013 - "Arsenic Trioxide (ATO) has shown remarkable efficacy for the treatment of multiple myeloma (MM). " 03/01/2004 - "Arsenic trioxide is effective in the treatment of multiple myeloma in SCID mice." 01/01/2006 - "Single-agent arsenic trioxide has shown promising results in patients with relapsed or refractory multiple myeloma (MM). " 08/01/2009 - "The efficacy of arsenic trioxide for the treatment of relapsed and refractory multiple myeloma: a systematic review." 06/01/2013 - "The purpose of the present study was to explore new therapeutic strategies based on As2O3 for human multiple myeloma. "
5.	Hepatocellular Carcinoma (Hepatoma) 05/31/2014 - "However, recent phase II trials demonstrated that single agent arsenic trioxide was poorly effective against hepatocellular carcinoma (HCC), which might be due to drug resistance. " 12/01/2016 - "SurvivinT34A increases the therapeutic efficacy of arsenic trioxide in mouse hepatocellular carcinoma models." 08/01/2011 - "ATO (arsenic trioxide) is used effectively in the treatment of HCC (hepatocellular carcinoma). " 06/01/2011 - "These results suggest that treating hepatoma with a combination of As2O3 and AZT offers the advantages of reduced toxic side effects and improved therapeutic efficacy. " 08/15/2023 - "To determine the safety and efficacy of transcatheter arterial chemoembolization with CalliSpheres® beads loaded with arsenic trioxide (CBATO-TACE) in the first-line treatment of patients with large (5 cm ≤ maximum diameter < 10 cm) or huge (maximum diameter ≥ 10 cm) hepatocellular carcinoma (HCC). "

Related Drugs and Biologics

1.	Arsenic Trioxide (Trisenox)
2.	Tretinoin (Retinoic Acid)
3.	Aligeron (AS 2)
4.	Arsenic
5.	Ascorbic Acid (Vitamin C)
6.	Anthracyclines
7.	Proteins (Proteins, Gene)
8.	Arsenicals (Arsenic Compounds)
9.	Antineoplastic Agents (Antineoplastics)
10.	Cytarabine (Cytosar-U)

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Remission Induction
4.	Aftercare (After-Treatment)
5.	Consolidation Chemotherapy